AML_targeted_resequencing_study
Genomic libraries will be generated from whole genome amplified genomic DNA derived from 3,000 myeloid neoplasms. Targeted capture will be performed by multiplexing 16 barcoded samples in each library. Pools of 96 DNA samples will be subjected to 1-2 lanes of HiSeq 75bp sequencing. Reads will be mapped to the current build of the human reference genome to facilitate the generation of a comprehensive catalog of somatic mutations associated with 116 known myeloid and cancer driver genes.
- Type: Cancer Genomics
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001000253 | Illumina HiSeq 2000 | - | |
EGAD00001000283 | Illumina HiSeq 2000 | 764 |
Publications | Citations |
---|---|
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
N Engl J Med 374: 2016 2209-2221 |
2091 |
Precision oncology for acute myeloid leukemia using a knowledge bank approach.
Nat Genet 49: 2017 332-340 |
142 |
Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia.
Haematologica 104: 2019 516-523 |
50 |
AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
Exp Hematol 87: 2020 13-19 |
10 |
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.
Nat Commun 12: 2021 7244 |
32 |
Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML.
Blood Adv 7: 2023 1040-1044 |
0 |